

Detection of Human Papillomavirus Genotypes in Breast Cancer Patients

Morvarid Golrokh Mofrad

Razi Vaccine and Serum Research Institute

Zohreh Azita Sadigh

Razi Vaccine and Serum Research Institute

Sanaz Ainechi

University of Southern California

Ebrahim Faghihloo (✉ faghihloo@gmail.com)

Shaheed Beheshti University of Medical Sciences <https://orcid.org/0000-0002-8669-305X>

Research

Keywords: human papillomavirus, HPV, breast cancer, genotype, herpes virus, PCR

Posted Date: December 13th, 2020

DOI: <https://doi.org/10.21203/rs.3.rs-38630/v4>

License: © ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Version of Record: A version of this preprint was published on January 22nd, 2021. See the published version at <https://doi.org/10.1186/s12985-021-01498-z>.

Abstract

Background: The role of viruses as a cause of breast cancer (BC) has been significantly investigated in recent years. Human papillomavirus (HPV) has been detected in invasive breast carcinomas, while most studies have only focused on the detection of viral DNA, we aimed to examine the prevalence and genotypes of HPV among Iranian BC patients.

Methods: We collected and analyzed 70 Formalin-Fixed Paraffin-Embedded (FFPE) blocks including 59 BC samples, and 11 benign breast lesions as control from Iranian patients using nested PCR. Real-time PCR utilized as a confirming test to nested PCR findings. Genotyping of HPV positive samples was performed, the samples were also subjected to a multiplex PCR to detect herpes simplex-1 (HSV-1), herpes simplex-2 (HSV-2), varicella zoster virus (VZV), and cytomegalovirus (CMV) in BC.

Results: Papillomavirus DNA was present in 7 of 59 BC samples (11.8%); while none was detected in control samples. The most prevalent type was HPV18, followed by HPV 6. All HPV positive patients had high tumor grades (II/ III) with a histologic diagnosis of ductal carcinoma. The patient age range was 33 to 73 years with a median of 51 years. Most of HPV positive patients had low levels of education. HPV16 was not detected. Also, 5 of 59 BC specimens (8.47%), were positive for HSV-1.

Conclusions: Our results suggest a carcinogenesis role for High-risk HPVs in breast tumors. Our findings of HSV-1 and low-risk HPVs in BCs may propose a cancer-causing role for them. Further large-scale studies are warranted to assess the significance of our findings.

Background

Breast Cancer (BC) is the most prevalent cancer worldwide among women. BC accounts for approximately 30% of female cancers and is the most frequent cause of death in women (1, 2). Over the last decade incidence rates of BC have raised by around 20% worldwide. Even though the incidence rate of BC is higher in developed countries, has higher mortality in developing countries. More than 55% of breast cancer-related deaths occur in them (3, 4). Lack of early detection programs, inadequate diagnostic and treatment facilities are the main reasons for the low survival rate in most developing countries (5, 6). The fifth most common cancer-related death in Iran is BC (7). Different factors, such as family history, genetics, decreased childbearing and breastfeeding, harmful dietary, previous benign breast disease, radiation, oral contraceptives, smoking, and alcohol intake are considered as risk factors in the onset of cancer (8-10). Meanwhile, a pathogenesis role for some infectious agents including viruses has been questioned (11-14).

Some studies have shown the role of human papillomavirus (HPV) in different cancers (15-17). Over the past two decades, various studies have suggested a role for HPV in breast cancer (18-22).

Thus far over 200 HPV types have been identified and most of them fall within three genera: alpha (α), beta (β), and gamma (γ). While alpha type (α) is mainly found on mucosal surfaces, beta (β) and gamma

(α) types are usually detected on the skin surface and in hair follicles (23, 24). HPVs are classified into low and high-risk types based on their oncogenic potential (25). Low-risk HPVs as the main pathogen in benign genital warts are not usually associated with any other neoplasms. Low risk HPVs include: 6, 11, 34, 40, 42, 43, 44, 53, 54, 66, 70, and 74. High risk HPV types named for their carcinogenicity, and comprised of 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68, and 69 (26, 27). For the first time in 1992, Di Leonardo A and colleagues suggested that HPV could play a crucial role in the genesis of breast carcinoma by detecting HPV16 DNA sequence in 29.4% of breast and lymph node samples (28). Following the first publication, several more studies have documented the presence of HPV in malignant breast tumors (29-31). On the contrary negative relationship between HPV and breast cancer has been declared by a few studies (32-34). Therefore, the association between HPV and breast carcinogenesis is not completely clear. Due to the high rate of breast cancer in Iranian women and the probable role of high-risk HPV in its carcinogenesis, we determined to investigate the presence of two high-risk genotypes; HPV16 and HPV18 in our study group.

Besides, we decided to investigate the presence of herpesviruses (HSV1, HSV2, VZV, and CMV) in our collected BC cases, as some studies have reported a relation between a group of herpesviruses and breast cancer(35-39).

Methods

Sample collection

This cross-sectional, case-control study was conducted in Modarres hospital, Tehran, Iran, on cases archived between 2008 and 2019 years. A total of 70 blocks of Formalin-Fixed Paraffin-Embedded (FFPE) including 59 samples diagnosed as breast carcinomas, and 11 benign breast lesions as control were collected from the pathology department archives of Modarres hospital. Also, several parameters; such as type of BC, grading of breast cancer, age, and level of education were taken in written format as exclusion criteria and summarized in Table 1. All study procedures are performed in laboratories of Shahid Beheshti Medical School of sciences.

DNA Extraction

The genomic DNA was extracted from FFPE breast tissues. Then we performed a standard polymerase chain reaction (PCR) to detect HPV DNA. To extract DNA, FFPE tissues were cut in 10 μ m thickness by a microtome. Deparaffinization was performed by adding 1 ml xylene and spinning. Afterwards, we centrifuged the samples for 5 min, and supernatants were removed. This step was repeated once, then 1 ml of 96% ethanol was added. Microtubes were put in a 50°C heating block until ethanol was entirely dried up. Then digestion was performed by adding digestion buffer and proteinase K solution. Later, the microtubes were incubated overnight, and the next day they were placed in a 95 °C heater. Respectively phenol, phenol-chloroform, and chloroform solutions were added to samples, each step followed by

centrifugation, and subsequent removal of the supernatant. Ultimately, ethanol was added, then they were kept overnight in an incubator.

Samples were centrifuged at 12000 g for 30 min on the last day of the extraction. After removing the supernatant, the uncapped microtubes were left in a 37 °C heater to let the residual ethanol to evaporate. Finally, distilled water was added and the DNA extracts were quantified with a NanoDrop spectrophotometer.

The quality of DNA extracted from paraffin-embedded tissue samples was assessed by a forward (ATGTTTCGTCATGGGTGTGAA) and reverse (GGTGCTAAGCAGTTGGTGGT) primer pair targeting a sequence within the GAPDH gene. PCR amplification protocol consisted of 30 cycles of denaturation at 95 °C for 30 s; hybridization at 55°C for 30 s, and elongation at 72°C for 30s. A final elongation step was performed at 72 °C for 10 min.

PCR for HPV and herpes viruses

All samples were screened for HPV L1 conserved region. The nested PCR assay was performed using two sets of primers (MY09/11 and GP5+/6+) for two consecutive amplification reactions. The first reaction was performed in 25 µl using 12.5 µl of master mix (which includes: 1X PCR buffer, 2 mM MgCl₂, 50 µM of each deoxynucleotide triphosphate (dNTP) and 2 U of Taq DNA polymerase (Takapouzist, Iran), 100-200 ng of template DNA, 10 pmol of each consensus outer degenerate primer MY09(5'-CGTCC(A/C)A(A/G)(A/G)GGA(A/T)ACTGATC-3') /MY11(5'-GC(A/C)CAGGG(A/T)CTATAA(C/T)AATGG-3') and distilled water. Thermal cycling (Bio Intellectica) performed with the following program: 5 min at 94 °C, 40 cycles of 1 min at 94 °C, 1 min at 55 °C, and 1 min at 72 °C, with a final extension step at 72 °C for 7 min.

The second reaction was also performed in 50 µl including 25 µl of master mix (which contains: 1X PCR buffer, 3 mM MgCl₂, 50 µM each dNTP, 2U Taq DNA polymerase), 100-200 ng of amplified DNA, and 10 pmol each inner consensus primer GP5+ (5'-TTTGTACTGTGGTAGATACTAC-3') and GP6+ (5'-AAAAATAA ACTGTAAATCATATTC-3'), and distilled water. Thermal cycling used the following program: 4 min at 94 °C, 40 cycles of 1 min at 94 °C, 2 min at 40 °C, and 2 min at 72 °C, with a final extension step at 72 °C for 4 min.

Negative controls containing water instead of DNA were used. We used the HPV18 HeLa cell line as a positive control.

Real-time PCR amplification was performed in a 20 µl volume containing 4 µl 5x HOT FIREPol® Probe qPCR Mix Plus (no ROX) (Solis BioDyne, Estonia), 0, 5 µl of each forward and reverse primers (Pishgam company, Tehran, Iran), 0.5 µl of probes (Sinaclon Co., Tehran, Iran) which listed in Table 2, and 2 µl of

each sample or control, and rest of the total volume was obtained by adding distilled water. Amplification and detection were performed by a real-time PCR machine (Rotor-Gene-Q 6000 thermocycler (Corbett, Australia)). Thermal cycles used for quantification of HPV18 E6 gene and HPV type 16 E7 gene were 95°C for 12 minutes, 95°C for 15 seconds, and 60°C for 60 seconds for 40 cycles.

Duplicate reactions for each gene were performed. Probes were labeled with 6-FAM at the 5' end and TAMRA at the 3' end.

Each PCR was performed with negative (DNA free water) and positive controls (genomic DNA of SiHa cells for HPV-16, and genomic DNA of HeLa cells for HPV-18).

The samples were also subjected to a multiplex PCR to detect HSV-1, HSV-2, VZV, and CMV. The PCR reactions were performed in a total volume of 25 µL containing 12.5 µl PCR Master Mix (10X PCR Taq polymerase buffer, 10mM of dNTPs and 1.5 U/rxn of Taq DNA polymerase [Takapouzist, Iran]), 10 pmol of each primer (HSV-1, HSV-2, CMV, and VZV) (Table2), and 50 ng of genomic DNA.

mPCR (multiplex PCR) conditions were as follows: Initial denaturation (95°C for 5min), 35 cycles of denaturation (95°C for 30sec) annealing (60°C for 30 seconds) and extension (72°C for 30 seconds); Final extension was given at 72°C for 10 minutes. Samples were preserved at 4°C and then the PCR product was detected by gel electrophoresis.

Sequencing and Phylogenetic Analysis

The positive PCR samples were sequenced for HPV genotypes. The DNA sequence was determined with the Big-Dye terminator cycle sequencing kit and an ABI 377A sequencer (Applied Biosystems Inc.).

The HPV sequences were edited with the BioEdit program version 7.2.3, and then phylogenetic and molecular analyses were organized using MEGA software program version 6.0.6 [27]. The neighbor joining and the Kimura 2-parameters methods were used for phylogenetic reconstructions that were implemented in the MEGA 6.0.6 program. Statistical significance for the phylogenetic tree was assessed by the bootstrap method (1000 replicates).

Data were analyzed by SPSS statistical software program version 16.0. The correlations were subjected to χ^2 (Pearson chi-square) and Fisher's exact test. Odds ratios and logistic regression were also calculated. Statistical significance was set as a *P*-value less than 0.05.

Deposit the nucleotide sequence

The nucleotide sequences of HPV isolates that were found out in this study have been settled in the GenBank database [accession numbers QED55703– QED55709]. The GenBank accession numbers for HPV6 types are QED55703 and QED55704, and for HPV18 types are QED55705, QED55706, QED55707, QED55708, and QED55709.

Results

Study population

HPV gene sequences were identified. The patient age range was between 29 to 81 years (mean of 50 years). Only 4 patients had low-grade malignancy (6.7%), and the remaining were diagnosed with high grade (93.3%). Regarding histologic types, 5% of tumors were lobular types, and the remaining (95 %) were ductal carcinomas (Table 3). We reviewed the level of education of patients and we found 24% with high education level (university degree), 56% with low education level (high school diploma or less), and 20% with no education.

Assessing DNA quality

After extracting DNA from 59 FFPE breast cancer samples, and 11 benign breast lesions as control, we used PCR for the GAPDH gene to check the quality of DNA samples. The amplification of the GAPDH gene (fragment size of 110 bp) was positive in all extracted DNA, indicating an adequate quality of DNA. (Fig1)

Detection of HPV and herpes viruses by PCR analysis

7 of the 59 BC samples (11.8%) were positive for HPV DNA. The outer consensus primers MY09/MY11, and GP5+/GP6+ inner primers were used in nested PCR. The length of products from the first and second steps of nested PCR was 450 bp and 150 bp respectively. None of the control samples were positive for HPV DNA (Fig2).

In our study, the age range of HPV positive patients was between 33 to 73 years (average age 51). All HPV positive patients had high tumor grades (II/ III). Histologic diagnosis of all positive cases was ductal carcinoma. Most of the patients had low levels of education (57.1%), 14.2% had no education and the remaining had a university degree (28.5%). (Table 3)

Analysis of real-time PCR supported the results of nested PCR and confirmed the presence of HPV18 in 5 breast tissue samples. HPV16 was not detected in any of the cases.

Herpes simplex 1 virus sequence was detected in 8.47% (5/59) of cases using mPCR (Fig3). None of the samples were positive for HSV-2, VZV, and CMV. The average age of HSV-1 positive patients was about 47 years. Most of the positive samples (80%) had high tumor grades (II/ III) (Table 3). Of the total of five cases, three had a low level of education, one had a university degree and one had no education. We verified the co-infection of HPV18 and HSV-1 in two of our cases (3.3%).

Sequencing and construction of the phylogenetic tree

All positive PCR products were sequenced. Five out of 7 HPV positive samples were HPV18 genotype (~72%), and the rest two (~28%) were HPV6 genotype. Phylogenetic tree was shown in Fig4.

Based on our findings, the most prevalent type was HPV18, followed by HPV 6. Contrary to our expectations, we didn't find any HPV16 genotype.

All of the HPV positive patients had invasive ductal carcinomas and high-grade tumors. The age range of 30 to 40 years had three positive samples; 2 of them were HPV18 and one of them was HPV6. The age range of 50 to 60 years had one HPV6 and one HPV18 positive samples. The age range of 60 to 70 years and 70 to 80 years, each with one HPV18 positive samples.

Discussion

The worldwide increase in incidence and mortality of breast cancer is considerable (40). This indicates the value of identifying responsible and preventable risk factors for breast cancer. Viral agents play a crucial role as carcinogens and they are associated with nearly 20% of cancers. The development of molecular techniques and subsequent investigations has proven the carcinogenic effect of high-risk HPV in various tumors, including breast carcinoma (41). Based on published theories HR-HPVs trigger cancer by modifying cellular pathways by over-expressing E6 and E7 oncoproteins and suppressing the immune system (42, 43). Numerous publications studied the association between HPV and cervical cancer (44-46). But the correlation between HPV and breast cancer remains controversial. Lonardo A and his colleagues questioned the role of HPV16 in breast cancer for the first time in 1992 by identifying the DNA of this virus in 29.4% of BC samples(28). Later, various studies were conducted worldwide. In 2011, according to a meta-analysis study, the prevalence of HPV in breast cancer in Europe was the lowest (12.91%), while was the highest in Oceania (42.11%) followed by Asia (32.42%) (47). Based on their statistics and our findings, Iranian women with breast cancer are more vulnerable to HPV infection than European women but less vulnerable compared to Australian and North American women. One-fourth of Iranian women with BC are infected with HPV coincidentally. The prevalence of HPV infection in Iranian women with BC shows variation among cities/districts as follow: Shiraz (South city) 5.5%, Mazandaran (Northern district) 25.9%, Kermanshah (western district) 62.1%, Mashhad (Northeast city) 26.2%, and

Tehran (Capital) 5.7%. (48-52). In this study, we surveyed women with BC in Tehran and our result showed the 11.8% prevalence of HPV. Our results are similar to the findings of a study conducted in the United States in 2019, which used multiplex PCR with HPV E6 or E7 gene-specific primers for 64 serum samples of BC patients. So they reported 5 BC patients with positive HPV DNA (7.8%) (53). Similarly, a study performed in 2011, detected 4 HPV DNA from 62 tumor tissue samples (6.5%) (54). In contrast, different reports from the United States, the United Kingdom, and Venezuela showed a higher percent of HPV prevalence in BCs; such as 86%, 42%, and 41.6%, respectively (29, 55, 56). On the other hand, several studies performed in Denmark, Australia, India, etc. couldn't find any association between the presence of HPV and breast cancer (32, 33, 57). Some studies declared that HPV6 (low-risk HPV) was the most common type of virus among their specimens (30, 58) since we also found HPV6 in our samples so we recommend considering low-risk HPVs in breast cancer studies. Our result was similar to N Khodabandehlou et al.,(59) and JS Lawson et al.,(60), which reported HPV18 as the most prevalent type in positive samples. Noticeably, we did not find HPV type 16, which was demonstrated to be prevalent in previous studies (61, 62).

Differences in results may be due to variation in patient age range, the geographical distribution of viruses, techniques, and the quality of samples used in each study. According to a few published papers, the mean age of breast cancer in Iranian women is between 47.95 to 54.6 years. (63-66). In our study, the age range of patients was from 29 to 81 years (mean of 50 years) while according to a study in 2008 in Syrian women, the age range was 26 to 66 (with a median age of 52) with a higher prevalence of HPV (61.06%) (67). Also, in our study, the age range of HPV-positive patients was from 33 to 73 years with a viral prevalence of 11.8%, but in a study in Venezuela, the age range was 51 to 60 years with a viral prevalence of 41.67% (55). Therefore, the age range can be considered as an important issue in the rate of viral detection.

BC is often labeled as a "welfare disease" because the incidence rate was reported higher in women in Western societies with higher social class and higher education. Of course, this can be related to timely diagnosis and regular checkups, as well as better training in this group(68).

But in 2017, J Bahk and colleagues conducted the age-period-cohort (APC) analysis in Korea. They reported the BC mortality was higher in women with higher education than in women with no education or a primary education during 1983-1992, and the reverse was true in 1993-2012(69).

In this study, a low level of education was found in 56%, and no education in 20% of patients. And in HPV-positive patients, 57.1% had low levels of education and 14.2% had no education. Regarding our results, most BC patients and HPV positive patients had low levels of education. Therefore, it can be noted that the education, training, and socioeconomic level of individuals can play a significant role in the prevention and timely treatment of breast cancer.

In this study, regarding histologic types, 95% of the total tumor specimens were ductal carcinoma and 5% were lobular carcinoma. And all positive HPV samples were ductal carcinoma. Similarly, in 2019, N

Khodabandehlou et al. showed ductal carcinoma as the most frequent type in their HPV-positive patients(59).

Also, in the UK base study, NA Salman reported a higher prevalence of HPVs in patients with invasive ductal carcinoma(56). From these studies, it can be concluded that mammary ducts provide an entry point for HPV infection(70).

Few studies surveyed the relation of tumor grades and HPV positive breast cancers. As the study of C Kroupis and et al. recorded high-grade tumors in 70.6% of HPV-positive breast cancer cases (61). In our study, all positive samples had a high-grade tumor.

Ni Li and colleagues stated a remarkable point about the type of samples collected for studies. They showed a higher prevalence of HPV DNA in FFPE samples than fresh samples (47) According to their findings the age of specimen also may affect the prevalence of virus detection. Our results indicated that samples collected earlier (from 2018 to 2019) showed higher HPV positivity compared to older collected samples (from 2008 to 2018).

Besides, due to the important role of herpesviruses as a co-factor in the oncogenesis of BC (39, 71, 72), we decided to detect this virus in our specimens. In 2013, BM Khashman et al. detected HSV-1 Ag with 31.8% prevalence using direct immunofluorescence in FFPE breast tissues (36). We suggest utilizing a different technique, since it may affect results. In the literature, several studies are investigating the relationship between HPV and herpesviruses (73, 74). So we used multiplex PCR with different primers for HSV-1, HSV-2, CMV, and VZV. We detected only HSV-1 with an 8.47% prevalence. Using an individual immunofluorescence method for each virus might be more specific and provide higher accuracy.

These data determine further evidence of a possible role for Human papillomavirus and Herpesvirus in breast carcinogenesis, however additional studies in a larger patient population and by techniques with higher specificities can ascertain our results. Also for early detection of cervical cancer, the American Cancer Society guidelines recommend Pap test and HPV DNA testing. Currently, the American Cancer Society recommends mammography for regular breast cancer screening, while further studies on the association between breast cancer and HPV in the future may add HPV screening to this guideline (75).

Conclusion

Overall, in the present study, we identified HPV18 and HPV6 genotypes in 11.8% of FFPE samples from women with breast cancer, and

HPV18 was the most common genotype. Most of the positive samples were in grade II and III. Also, HSV-1 was detected in 8.47% of BC samples. And coinfection of HPV and HSV-1 was declared in 3.3% of them. More epidemiological and molecular studies with large samples are needed to validate the association of breast cancer and HPV genotypes, and the role of coinfection of HPV and herpesviruses in the carcinogenesis of breast cancer.

Declarations

Ethics approval and consent to participate

The study was approved by the ethical committee of Shahid Beheshti University of Medical Sciences, Tehran, Iran under the Ethics code of IR.SBMU.MSP.REC.1397.49

Consent for publication

Not applicable.

Availability of data and material

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Competing interests

The authors declare that they have no competing interests.

Funding

This article is financially supported by “Research Department of the School of Medicine Shahid Beheshti University of Medical Sciences” (Grant No 14847).

Authors' contributions

Morvarid Golrokh Mofrad collected the samples and analyze them, and wrote the manuscript; Zohreh Azita Sadigh, Sanaz Ainechi, and Ebrahim Faghihloo revised the manuscript. All authors read and approved the final manuscript.

Acknowledgments

Not applicable.

Abbreviations

Human papillomavirus (HPV), breast cancer (BC), herpes simplex virus (HSV), cytomegalovirus (CMV), varicella zoster virus (VZV), high risk (HR), low risk (LR), Formalin-Fixed Paraffin-Embedded (FFPE), polymerase chain reaction (PCR), multiplex polymerase chain reaction (mPCR), Glyceraldehyde-3-phosphate dehydrogenase (GAPDH), base pair (bp), minute (min), distilled water

(dH₂O).

References

1. Tarver T. Cancer facts & figures 2012. American cancer society (ACS) Atlanta, GA: American Cancer Society, 2012. 66 p., pdf. Available from. Taylor & Francis; 2012.
2. McPherson K, Steel C, Dixon J. ABC of breast diseases: breast cancer—epidemiology, risk factors, and genetics. *BMJ: British Medical Journal*. 2000;321(7261):624.
3. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. *CA: a cancer journal for clinicians*. 2005;55(2):74-108.
4. Jakesz R. Breast cancer in developing countries: challenges for multidisciplinary care. *Breast Care*. 2008;3(1):4-5.
5. Allemani C, Weir HK, Carreira H, Harewood R, Spika D, Wang X-S, et al. Global surveillance of cancer survival 1995–2009: analysis of individual data for 25 676 887 patients from 279 population-based registries in 67 countries (CONCORD-2). *The Lancet*. 2015;385(9972):977-1010.
6. Sankaranarayanan R, Swaminathan R, Brenner H, Chen K, Chia KS, Chen JG, et al. Cancer survival in Africa, Asia, and Central America: a population-based study. *The lancet oncology*. 2010;11(2):165-73.
7. Taghavi A, Fazeli Z, Vahedi M, Baghestani AR, Pourhoseingholi A, Barzegar F, et al. Increased trend of breast cancer mortality in Iran. *Asian Pacific Journal of Cancer Prevention*. 2012;13(1):367-70.
8. Parkin DM, Fernández LM. Use of statistics to assess the global burden of breast cancer. *The breast journal*. 2006;12:S70-S80.
9. McPherson K, Steel C, Dixon J. Breast cancer—epidemiology, risk factors, and genetics. *Bmj*. 2000;321(7261):624-8.
10. Tavakolian S, Goudarzi H, Torfi F, Faghihloo E. Evaluation of microRNA-9 and-192 expression levels as biomarkers in patients suffering from breast cancer. *Biomedical Reports*. 2020;12(1):30-4.
11. Lawson JS, Glenn WK. Multiple oncogenic viruses are present in human breast tissues before development of virus associated breast cancer. *Infectious agents and cancer*. 2017;12(1):55.
12. Lehrer S, Rheinstein PH. The virology of breast cancer: viruses as the potential causative agents of breast tumorigenesis. *Discovery medicine*. 2019;27(148):163.
13. Tavakolian S, Goudarzi H, Faghihloo E. Evaluating the expression level of HERV-K env, np9, rec and gag in breast tissue. *Infectious Agents and Cancer*. 2019;14(1):42.

14. Golrokh Mofrad M, Kazeminezhad B, Faghihloo E. Prevalence of Epstein–Barr virus (EBV) in Iranian breast carcinoma patients. *Asian Pacific Journal of Cancer Prevention*. 2020;21(1):133-7.
15. Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S. Human papillomavirus and cervical cancer. *The Lancet*. 2007;370(9590):890-907.
16. Castellsagué X, Alemany L, Quer M, Halc G, Quirós B, Tous S, et al. HPV involvement in head and neck cancers: comprehensive assessment of biomarkers in 3680 patients. *Journal of the National Cancer Institute*. 2016;108(6):djv403.
17. Mofrad MG, Maleki DT, Faghihloo E. The roles of programmed death ligand 1 in virus-associated cancers. *Infection, Genetics and Evolution*. 2020:104368.
18. Damin AP, Karam R, Zettler CG, Caleffi M, Alexandre CO. Evidence for an association of human papillomavirus and breast carcinomas. *Breast cancer research and treatment*. 2004;84(2):131-7.
19. Widschwendter A, Brunhuber T, Wiedemair A, Mueller-Holzner E, Marth C. Detection of human papillomavirus DNA in breast cancer of patients with cervical cancer history. *Journal of Clinical Virology*. 2004;31(4):292-7.
20. Søgaard M, Farkas DK, Ording AG, Sørensen HT, Cronin-Fenton DP. Conisation as a marker of persistent human papilloma virus infection and risk of breast cancer. *British journal of cancer*. 2016;115(5):588.
21. ElAmrani A, Gheit T, Benhessou M, McKay-Chopin S, Attaleb M, Sahraoui S, et al. Prevalence of mucosal and cutaneous human papillomavirus in Moroccan breast cancer. *Papillomavirus Research*. 2018;5:150-5.
22. Li J, Ding J, Zhai K. Detection of human papillomavirus DNA in patients with breast tumor in China. *PLoS One*. 2015;10(8):e0136050.
23. Bernard H-U, Burk RD, Chen Z, Van Doorslaer K, Zur Hausen H, de Villiers E-M. Classification of papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic amendments. *Virology*. 2010;401(1):70-9.
24. Sichero L, Campbell CMP, Fulp W, Ferreira S, Sobrinho JS, Baggio ML, et al. High genital prevalence of cutaneous human papillomavirus DNA on male genital skin: the HPV Infection in Men Study. *BMC infectious diseases*. 2014;14(1):677.
25. Cogliano V, Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F. Carcinogenicity of human papillomaviruses. *The lancet oncology*. 2005;6(4):204.
26. Zur Hausen H. Papillomavirus infections—a major cause of human cancers. *Biochimica et biophysica acta (BBA)-reviews on cancer*. 1996;1288(2):F55-F78.
27. Ramanakumar AV, Naud P, Roteli-Martins CM, de Carvalho NS, de Borba PC, Teixeira JC, et al. Incidence and duration of type-specific human papillomavirus infection in high-risk HPV-naïve women: results from the control arm of a phase II HPV-16/18 vaccine trial. *BMJ open*. 2016;6(8):e011371.
28. Di Lonardo A, Venuti A, Marcante ML. Human papillomavirus in breast cancer. *Breast cancer research and treatment*. 1992;21(2):95-100.

29. de Villiers E-M, Sandstrom RE, zur Hausen H, Buck CE. Presence of papillomavirus sequences in condylomatous lesions of the mamillae and in invasive carcinoma of the breast. *Breast cancer research*. 2004;7(1):R1.
30. Cavalcante JR, Pinheiro LGP, Almeida PRCd, Ferreira MVP, Cruz GA, Campelo TA, et al. Association of breast cancer with human papillomavirus (HPV) infection in Northeast Brazil: molecular evidence. *Clinics*. 2018;73.
31. Saeed M, Zer Y, Bozdağ Z. Investigation of the Relationship between Breast Cancers and HPVs. *Universal Journal of Clinical Medicine*. 2018;6(1):1-9.
32. Bønløkke S, Blaakær J, Steiniche T, Høgdall E, Jensen SG, Hammer A, et al. evidence of no association Between human Papillomavirus and Breast cancer. *Frontiers in oncology*. 2018;8.
33. Hedau S, Kumar U, Hussain S, Shukla S, Pande S, Jain N, et al. Breast cancer and human papillomavirus infection: no evidence of HPV etiology of breast cancer in Indian women. *BMC cancer*. 2011;11(1):27.
34. Wrede D, Luqmani Y, Coombes R, Vousden K. Absence of HPV 16 and 18 DNA in breast cancer. *British journal of cancer*. 1992;65(6):891.
35. Richardson A. Is breast cancer caused by late exposure to a common virus? *Medical hypotheses*. 1997;48(6):491-7.
36. Khashman BM. Detection of herpes simplex virus-1 antigen in tissues of breast cancer. *Diyala Journal of Medicine*. 2013;4(1):87-93.
37. Richardson A, Cox B, McCredie M, Dite G, Chang J, Gertig D, et al. Cytomegalovirus, Epstein–Barr virus and risk of breast cancer before age 40 years: a case–control study. *British journal of cancer*. 2004;90(11):2149.
38. Richardson AK, Currie MJ, Robinson BA, Morrin H, Phung Y, Pearson JF, et al. Cytomegalovirus and Epstein-Barr virus in breast cancer. *PloS one*. 2015;10(2):e0118989.
39. Eghbali M, Mehrjardi AZ, Mirinargesi M, Golijani R. Detection of varicella zoster virus (Vzv) in the benign and malignant breast tumors by polymerase chain reaction. 2012.
40. Benson JR, Jatoi I. The global breast cancer burden. *Future oncology*. 2012;8(6):697-702.
41. zur Hausen H. Papillomaviruses in the causation of human cancers—a brief historical account. *Virology*. 2009;384(2):260-5.
42. DeFilippis RA, Goodwin EC, Wu L, DiMaio D. Endogenous human papillomavirus E6 and E7 proteins differentially regulate proliferation, senescence, and apoptosis in HeLa cervical carcinoma cells. *Journal of virology*. 2003;77(2):1551-63.
43. Ryser MD, Myers ER, Durrett R. HPV clearance and the neglected role of stochasticity. *PLoS computational biology*. 2015;11(3):e1004113.
44. Munoz N, Bosch X, Kaldor J. Does human papillomavirus cause cervical cancer? The state of the epidemiological evidence. *British Journal of Cancer*. 1988;57(1):1.

45. Wardak S. Human Papillomavirus (HPV) and cervical cancer. *Medycyna doświadczalna i mikrobiologia*. 2016;68(1):73-84.
46. Bosch FX, De Sanjosé S. Human papillomavirus in cervical cancer. *Current oncology reports*. 2002;4(2):175-84.
47. Li N, Bi X, Zhang Y, Zhao P, Zheng T, Dai M. Human papillomavirus infection and sporadic breast carcinoma risk: a meta-analysis. *Breast cancer research and treatment*. 2011;126(2):515-20.
48. Safaei A, Khanlari M, Momtahn M, Monabati A, Robati M, Amooei S, et al. Prevalence of high-risk human papillomavirus types 16 and 18 in healthy women with cytologically negative pap smear in Iran. *Indian Journal of Pathology and Microbiology*. 2010;53(4):681.
49. Sigaroodi A, Nadji SA, Naghshvar F, Nategh R, Emami H, Velayati AA. Human papillomavirus is associated with breast cancer in the north part of Iran. *The Scientific World Journal*. 2012;2012.
50. Jalilian S, Izadi B, Madani SH, Mohajeri P. The prevalence and genotype distribution of human papillomavirus types in the general female population in West of Iran. *Jundishapur Journal of Microbiology*. 2017;10(3).
51. Salehpour M, Meibodi NT, Teimourpour R, Ghorani-Azam A, Sepahi S, Rostami S, et al. Frequency of Human Papillomavirus Genotypes 6, 11, 16, 18 And 31 in Paraffin-Embedded Tissue Samples of Invasive Breast Carcinoma, North-East of Iran. *Iranian journal of pathology*. 2015;10(3):192.
52. JAMALI ZM, Hamkar R, GHOBADI DV, DELFOROUSH M, SHOJA MM, MODARES GM. Prevalence of HPV infection and its association with cytological abnormalities of Pap smears in Tehran. 2008.
53. Bravaccini S, Ravaioli S, Rocca A, Maltoni R, Cristalli C, Marasco E, et al. Abstract P2-04-01: Human papillomavirus (HPV) DNA detection in breast cancer by liquid biopsy: Something new on the horizon? : AACR; 2019.
54. Mou X, Chen L, Liu F, Shen Y, Wang H, Li Y, et al. Low prevalence of human papillomavirus (HPV) in Chinese patients with breast cancer. *Journal of International Medical Research*. 2011;39(5):1636-44.
55. Fernandes A, Bianchi G, Feltri AP, Pérez M, Correnti M. Presence of human papillomavirus in breast cancer and its association with prognostic factors. *ecancermedicalscience*. 2015;9.
56. Salman NA, Davies G, Majidy F, Shakir F, Akinrinade H, Perumal D, et al. Association of high risk human papillomavirus and breast cancer: a UK based study. *Scientific reports*. 2017;7:43591.
57. Gannon OM, Antonsson A, Milevskiy M, Brown MA, Saunders NA, Bennett IC. No association between HPV positive breast cancer and expression of human papilloma viral transcripts. *Scientific reports*. 2015;5:18081.
58. Ahangar-Oskouee M, Shahmahmoodi S, Jalilvand S, Mahmoodi M, Ziaee AA, Esmaeili H-A, et al. No detection of 'high-risk' human papillomaviruses in a group of Iranian women with breast cancer. *Asian Pac J Cancer Prev*. 2014;15(15):4061-5.
59. Khodabandehlou N, Mostafaei S, Etemadi A, Ghasemi A, Payandeh M, Hadifar S, et al. Human papilloma virus and breast cancer: the role of inflammation and viral expressed proteins. *BMC cancer*. 2019;19(1):61.

60. Lawson JS, Glenn WK, Salyakina D, Delprado W, Clay R, Antonsson A, et al. Human papilloma viruses and breast cancer. *Frontiers in oncology*. 2015;5:277.
61. Kroupis C, Markou A, Vourlidis N, Dionyssiou-Asteriou A, Lianidou ES. Presence of high-risk human papillomavirus sequences in breast cancer tissues and association with histopathological characteristics. *Clinical biochemistry*. 2006;39(7):727-31.
62. Elnoubi OAE, Eltyeb, R, Nuri BM, Alkhanjaf AAM. Genotyping of Human Papilloma Virus (HPV) Isolated from Breast Cancer Patients in Radiation and Isotopes Center Khartoum (RICK)–Sudan. *Int J of Multidisciplinary and Current research*. 2017;5.
63. Movahedi M, Haghighat S, Khayamzadeh M, Moradi A, Ghanbari-Motlagh A, Mirzaei H, et al. Survival rate of breast cancer based on geographical variation in Iran, a national study. *Iranian Red Crescent Medical Journal*. 2012;14(12):798.
64. Shahidsales S, Hosseini S, Ahmadi-Simab S, Ghavam-Nasiri M. The importance of Prognostic factors (ER, PR, P53) in breast cancer and their relationship with stage of disease. *medical journal of mashhad university of medical sciences*. 2014;57(2):457-63.
65. Arab M, Noghabaei G, Kazemi SN. Comparison of crude and age-specific incidence rates of breast, ovary, endometrium and cervix cancers in Iran, 2005. *Asian Pac J Cancer Prev*. 2014;15(6):2461-4.
66. Montazeri A, Vahdaninia M, Harirchi I, Harirchi AM, Sajadian A, Khaleghi F, et al. Breast cancer in Iran: need for greater women awareness of warning signs and effective screening methods. *Asia Pacific family medicine*. 2008;7(1):6.
67. Akil N, Yasmeen A, Kassab A, Ghabreau L, Darnel A, Al Moustafa A. High-risk human papillomavirus infections in breast cancer in Syrian women and their association with Id-1 expression: a tissue microarray study. *British journal of cancer*. 2008;99(3):404-7.
68. *Epidemiology Cf. Cancer incidence in Sweden*. 1998.
69. Bahk J, Jang S-M, Jung-Choi K. Increased breast cancer mortality only in the lower education group: age-period-cohort effect in breast cancer mortality by educational level in South Korea, 1983-2012. *International journal for equity in health*. 2017;16(1):56.
70. Heng B, Glenn W, Ye Y, Tran B, Delprado W, Lutze-Mann L, et al. Human papilloma virus is associated with breast cancer. *British journal of cancer*. 2009;101(8):1345-50.
71. Tsai J-H, Hsu C-S, Tsai C-H, Su J-M, Liu Y-T, Cheng M-H, et al. Relationship between viral factors, axillary lymph node status and survival in breast cancer. *Journal of cancer research and clinical oncology*. 2007;133(1):13-21.
72. Pasquereau S, Al Moussawi F, Karam W, Assaf MD, Kumar A, Herbein G. Cytomegalovirus, macrophages and breast cancer. *The open virology journal*. 2017;11:15.
73. Zhao Y, Cao X, Zheng Y, Tang J, Cai W, Wang H, et al. Relationship between cervical disease and infection with human papillomavirus types 16 and 18, and herpes simplex virus 1 and 2. *Journal of medical virology*. 2012;84(12):1920-7.
74. Mäki J, Paavilainen H, Kero K, Hukkanen V, Syrjänen S. Herpes simplex and human papilloma virus coinfections in oral mucosa of men—A 6-year follow-up study. *Journal of medical virology*.

2018;90(3):564-70.

75. Smith RA, Andrews KS, Brooks D, Fedewa SA, Manassaram-Baptiste D, Saslow D, et al. Cancer screening in the United States, 2019: A review of current American Cancer Society guidelines and current issues in cancer screening. CA: a cancer journal for clinicians. 2019;69(3):184-210.

Tables

Table 1. Clinical and Pathological Features of all cases

	Tumor cases	control cases
Numbers	59	11
Age ranges	29 to 81 years	33 to 69 years
Histological types	5% lobular 95% ductal	benign breast lesions
Grade	6/8% Low grade 93/2% High grade	
Levels of education	56% low level of education 24% high level of education 20% no education	54% low level of education 46% high level of education

L: Low grade (I), H: High grade (II/ III)

Table 2. List of Primers used for GAPDH PCR, nested PCR, real-time PCR, and multiplex PCR

Assay	Name	Sequence (5' → 3')
GAPDH (110 bp)	GAPDH-F	ATGTTTCGTCATGGGTGTGAA
	GAPDH-R	GGTGCTAAGCAGTTGGTGGT
MY09/11 (450 bp)	MY09	CGTCC (A/C) A (A/G) (A/G) GGA (A/T) ACTGATC
	MY11	GC (A/C) CAGGG (A/T) CTATAA(C/T) AATGG
GP5+/GP6+ (150 bp)	GP5+	TTTGTTACTGTGGTAGATACTAC
	GP6+	AAAAATAAACTGTAAATCATATTC
HPV 18 E6 (78 bp)	HPV 18 E6-F	CTG GGC ACT ATA GAG GCC AGT
	HPV 18 E6-R	GTG TTT CTC TGC GTC GTT GG
	HPV 18 E6-P	[FAM] -TGCAACCGAGCACGACAGGAACGA - [TAMRA]
HPV 16 E7 (98 bp)	HPV 16 E7-F	GAG GAG GAG GAT GAA ATA GAT GGT
	HPV 16 E7-R	AGC GTA GAG TCA CAC TTG CAA CA
	HPV 16 E7-P	[FAM] -CTCTGTCCGGTTCTGCTTGTCCAGCT- [TAMRA]
HSV-1 (269 bp)	HSV-1-F	GACTCTCCCACCGCCATCAG
	HSV-1-R	TGTCTTCGGGCGACTGGT

HSV-2	HSV-2-F	TATGCCTATCCCCGGTTGGA
(715 bp)	HSV-2-R	CGTGCCATCCGAATAAACGTG
VZV	VZV-F	TTGTGTCGGTCTCTCCAAGC
(934 bp)	VZV-R	TACGTCTTCAACCTCACGCC
CMV	CMV-F	TGGCTTTTCTTGAACGTGCG
(716 bp)	CMV-R	CCTTGACGCTGGTTTGGTTG

F: Forward primer, R: Reverse primer, P: Probe, FAM: 6-carboxy fluorescein, TAMRA: 6-carboxy tetramethyl rhodamine, bp: base pair

Table 3. Clinical and Pathological Features of positive cases

	Tumor cases	control cases	tumor grade Low (I)/ High (II/ III)	histological type lobular/ ductal
Total cases	59	11	6/8% L, 93/2% H	5% lobular, and 95% ductal
HPV-positive	7	0	100% H	100% ductal
HPV-negative	52	11	7/7% L and 92/3% H	
HSV-1-positive	5	0	80% H and %20 L	100% ductal
HSV-1-negative	54	11	5/6% L and 94/4% H	

HSV-2-positive	0	0	-	-
HSV-2-negative	59	11	-	-
VZV-positive	0	0	-	-
VZV-negative	59	11	-	-
CMV-positive	0	0	-	-
CMV-negative	59	11	-	-

L: Low grade (I), H: High grade (II/ III)

Figures




Figure 1

An agarose gel electrophoretogram of amplified GAPDH after the PCR as described in the materials and methods. Lanes 19 to 28 breast cancer samples, last lane: 100-bp DNA ladder.




Figure 2

An agarose gel electrophoretogram of amplified DNA after the nested PCR as described in the materials and methods. C+ Lane: positive control (hpv18 HeLa cell line), Lanes 1 to 13 breast cancer samples, c- lane: negative control, last lane: 100-bp DNA ladder.




Figure 3

Gel electrophoresis of the multiplex PCR amplification products. Lanes 19 to 26 breast cancer samples. The amplicon length was 269bp. c+ lane: positive control, c- lane: negative control, last lane: 100-bp DNA ladder.




Figure 4

Phylogenetic trees of HPV16 and HPV18 Based on L1 Nucleotide were Constructed Using neighbor joining method and the Kimura 2-Parameter model by MEGA 6 package.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [nanodroppicture.jpg](#)